Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model

Neuroscience Letters

Volumn 401, Issue 1-2, 2006, Pages 130-135

  Klein, Ronald L ^a   Dayton, Robert D ^a   Henderson, Karen M ^a   Petrucelli, Leonard ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adeno associated virus; Gene therapy; Neurodegenerative disease; Parkin; Substantia nigra; Tau

Indexed keywords

DOPAMINE; PARKIN; TAU PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE TRANSFER; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

ADENOVIRIDAE; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DOPAMINE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TAU PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 33646408797     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.03.001     Document Type: Article

References (30)

1. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000) 95-130
2. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., and Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12 (2003) 517-526
3. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
4. Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D.G., Pramstaller P.P., Zanusso G., Ajmar F., and Mandich P. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 47 (2000) 374-377
5. Dickson D.W. Tau and synuclein and their role in neuropathology. Brain Pathol. 9 (1999) 657-661
6. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., and Lee V.M. Initiation and synergistic fibrillization of tau and α-synuclein. Science 300 (2003) 636-640
7. Greene J.C., Whitworth A.J., Andrews L.A., Parker T.J., and Pallanck L.J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14 (2005) 799-811
8. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., and Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophilia parkin mutants. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4078-4083
9. Hyun D.H., Lee M., Halliwell B., and Jenner P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. J. Neurosci. Res. 82 (2005) 232-244
10. Hyun D.H., Lee M., Hattori N., Kubo S., Mizuno Y., Halliwell B., and Jenner P. Effect of wt or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J. Biol. Chem. 277 (2002) 28572-28577
11. Klein R.L., Dayton R.D., Leidenheimer N.J., Jansen K., Golde T.E., and Zweig R.M. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol. Therapy 13 (2006) 517-527
12. Klein R.L., Dayton R.D., Lin W.L., and Dickson D.W. Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol. Dis. 20 (2005) 64-73
13. Klein R.L., Lin W.L., Dickson D.W., Lewis J., Hutton M., Duff K., Meyer E.M., and King M.A. Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am. J. Pathol. 164 (2004) 347-353
14. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Murphy M.P., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expression mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
15. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., and Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17510-17515
16. Mandel R.J., and Burger C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6 (2004) 482-490
17. Manfredsson F.P., Lewin A.S., Muzyczka N., Burger C., and Mandel R.J. rAAV-mediated nigral parkin over-expression is neuroprotective in the 6-OHDA rat model of Parkinson's disease. Mol. Therapy 11 Suppl. 1 (2005) 24-25
18. Mirra S.S., Murrell J.R., Gearing M., Spillantini M.G., Goedert M., Crowther R.A., Levey A.I., Jones R., Green J., Shoffner J.M., Wainer B.H., Schmidt M.L., Trojanowski J.Q., and Ghetti B. Tau pathology in a family with dementia and a P301L mutation in tau. J. Neuropathol. Exp. Neurol. 58 (1999) 335-345
19. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 (2004) 18614-18622
20. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Sydney
21. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., De Lucia M., McGowan E., Lewis J., Prihar G., Kim J., Dillmann W.H., Browne S.E., Hall A., Voellmy R., Tsuboi Y., Dawson T.M., Wolozin B., Hardy J., and Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 (2004) 703-714
22. Petrucelli L., O'Farrell C., Lockhart R.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., and Cookson M.R. Parkin protects against the toxicity associated with mutant a-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
23. Poorkaj P., Muma N.A., Zhukareva V., Cochran E.J., Shannon K.M., Hurtig H., Koller W.C., Bird T.D., Trojanowski J.Q., Lee V.M., and Schellenberg G.D. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann. Neurol. 52 (2002) 511-516
24. Schneider J.A., Bienias J.L., Gilley D.W., Kvarnberg D.E., Mufson E.J., and Bennett D.A. Improved detection of SN pathology in Alzheimer's disease. J. Histochem. Cytochem. 50 (2002) 99-106
25. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacker A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
26. Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E., and Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37 (2003) 735-749
27. Wakabayashi K., Oyanagi K., Makifuchi T., Ikuta F., Homma A., Homma Y., Horikawa Y., and Tokiguchi S. Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations. Acta Neuropathol. 87 (1994) 545-553
28. Whitworth A.J., Theodore D.A., Greene J.C., Benes H., Wes P.D., and Pallanck L.J. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophilia model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8024-8029
29. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16 (2005) 262-270
30. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924